Clinical Trial Detail

NCT ID NCT03644589
Title Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Washington
Indications

triple-receptor negative breast cancer

Therapies

Cisplatin + Pembrolizumab

Age Groups: senior adult

No variant requirements are available.